TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on…
Pharmaceuticals, Biotechnology and Life Sciences
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on…
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – –…
Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead…
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnershipSAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE)…
Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate…
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024,…
BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today…
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology…
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1…
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential…